91251-45-5

Basic information

• Product Name: Benzenebutanol, 4-amino-
• CAS NO: 91251-45-5
• Molecular Formula: C10H15NO
• Molecular Weight: 165.235
• Mol File: 91251-45-5.mol
• Article Data: 11

Chemical Properties

• CAS DataBase Reference: Benzenebutanol, 4-amino-(CAS DataBase Reference)
• NIST Chemistry Reference: Benzenebutanol, 4-amino-(91251-45-5)
• EPA Substance Registry System: Benzenebutanol, 4-amino-(91251-45-5)

Safety Data

• Hazardous Substances Data: 91251-45-5(Hazardous Substances Data)

Upstream product

• 586-78-7 para-nitrophenyl bromide 
• 79524-20-2 4-(4-nitrophenyl)-1-butanol 
• 540-37-4 p-aminoiodobenzene 
• 872188-88-0 4-(4-aminophenyl)-3-butyn-1-ol 
• 15118-60-2 4-(4-aminophenyl)butyric Acid 

Downstream Products

• 152713-23-0 O-Ethyl S-xanthate 
• 1052138-70-1 4-(4-azidophenyl)butan-1-ol 
• 1052119-86-4 C₅₂H₈₈N₆O₁₃ 
• 1052138-75-6 1-[4-(4-azidobutyl)phenyl]-4-trimethylsilanyl-1H-[1,2,3]triazole 

Relevant articles and documents

HETEROCYCLIC MITOCHONDRIAL ACTIVITY INHIBITORS AND USES THEREOF

Heterocyclic compounds of Formula (I) and pharmaceutically acceptable salt thereof are disclosed. The use of such heterocyclic compounds and pharmaceutically acceptable salt thereof for the treatment of cancers, and more particularly cancers sensitive to mitochondrial activity inhibition and increased reactive oxygen species (ROS) levels, is also disclosed. Such cancers include acute myeloid leukemia (AML), preferably AML characterized by certain features, such as high level of expression of one or more Homeobox (HOX)-network genes, high and/or low expression of specific genes, the presence of one or more cytogenetic or molecular risk factors such as intermediate cytogenetic risk, Normal Karyotype (A/K), mutated NPM1, mutated CEBPA, mutated FLT3, mutated DNMT3A, mutated TET2, mutated IDH1, mutated IDH2, mutated RUNX1, mutated WT1, mutated SRSF2, intermediate cytogenetic risk with abnormal karyotype (intern(abnK)), trisomy 8 (+8) and/or abnormal chromosome (5/7), and/or a high leukemic stem cell (LSC) frequency.

Maytansinoid derivatives with peptide linker and conjugates thereof

The invention relates to novel cell-binding agent-cytotoxic agent conjugate having a peptide linkers and more specifically to conjugates of formula (I). The invention also provides novel cytotoxic agents of formula (II), linker compounds represented by fo

MACROLIDE COMPOUNDS AND METHODS OF MAKING AND USING THE SAME

The present invention provides amide containing macrocyclic compounds useful as therapeutic agents. More particularly, these compounds are useful as anti-infective, anti-proliferative, anti-inflammatory, and prokinetic agents.